Clinical Trials Browser

Phase 1 × INDUSTRY × birinapant × Clear all

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT00993239 2016-03-03

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Phase 1 Completed

50 enrolled

Tumor-Agnostic

Neoplasms

NCT01940172 2016-01-14

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Phase 1 Completed

27 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms